Printer Friendly

Nanogen issued patent for fluorescent method of monitoring PCR.

Nanogen, Inc. (San Diego, CA) announced that it was issued United States Patent 6,911,310, "Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system" by the United States Patent and Trademark Office. The '310 patent relates to a method of monitoring polymerase chain reaction (PCR) amplification of nucleic acid (DNA or RNA) using fluorescent resonant energy transfer (FRET), which is an essential part of molecular diagnostics. Marking the 131st patent to issue to Nanogen, it is closely related to the patents previously issued that describe nanofabrication and self-assembly of photonic molecular structures.

The method described in the '310 patent allows hybridization of DNA to be detected while conducting PCR. The process begins with oligonucleotides that are labeled with donor or acceptor fluorophores, each fluorophore illuminating at a unique wavelength of light upon excitation. When a donor fluorophore is excited, it absorbs energy and transfers it to an acceptor fluorophore that is located within a specific distance to the donor. Energy transfer is permitted in this way when two oligonucleotides, one labeled with a donor fluorophore and one with an acceptor fluorophore, are hybridized to a target nucleic acid. Hybridization places the donor and acceptor fluorophores within transfer distance from each other. The transfer of energy brings a shift in the emitted wavelength that can be detected as a change in the color of the light. In the absence of a target, no energy transfer or change in color occurs. By measuring the emission wavelength that results from the energy transfer to the acceptor fluorophore, the presence of the target nucleic acid can be detected.

"Nanogen's research in nanotechnology and fluorescent energy transfer is the continuation of many years of work," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "Our growing intellectual property estate includes valuable technologies involving methods of fluorescent energy transfer that can be used for the creation of useful DNA diagnostic assay systems."

Nanogen's advanced diagnostics provide researchers, clinicians, physicians and patients worldwide with improved methods and tests that can predict, diagnose and ultimately help treat disease. Nanogen's products include real-time PCR reagents, the NanoChip Molecular Biology Workstation platform for molecular diagnostic applications and its line of rapid point-of-care diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries.

Nanogen, Inc., +1-858-410-4600 www.nanogen.com
COPYRIGHT 2005 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Jun 1, 2005
Words:397
Previous Article:New River agrees with Gallo Center to reduce opioid tolerance.
Next Article:GSK exercises option to LymphoStat-B.
Topics:


Related Articles
Companies. (Random Samples).
Nanogen issued patent for addressable biologic electrode.
Apply new nucleic acid-based technologies to detection.
Nanogen issued patent for device that combines optical waveguides and molecular diagnostics.
Nanogen issued patents for biomarker discovery and nucleic acid manipulation technologies.
Nanogen announces patent for fluorescent detection of nucleic acid targets.
Nanogen issued patent for technology enabling assay development to detect difficult nucleic acid sequences.
Nanogen expands patent portfolio in genetic analysis technologies.
Nanogen releases enterovirus reagent employing newly patented hybridization technology.
Nanogen earns patents for use of biomarkers related to diabetes and Alzheimers Disease.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters